ArticleEJNMMI research2023
Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of
Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Alterations in peripheral blood inflammatory mediators, vascular endothelial growth factor, and serum tumor markers in advanced non-small cell lung cancer patients treated with bevacizumab combined with chemotherapy.American journal of translational research · 2026Article
- Effectiveness and safety of recombinant human endostatin injection plus immune checkpoint inhibitors for non-small cell lung cancer: a single-centered, retrospective study.American journal of cancer research · 2026Article
- Diagnostic, Therapeutic, and Prognostic Applications of Artificial Intelligence (AI) in the Clinical Management of Brain Metastases (BMs).Brain sciences · 2025Review
- Clinical effectiveness of Anlotinib combined with PD-1 inhibitors in treating advanced non-small-cell lung carcinoma.American journal of translational research · 2025Article
- Analysis of variation of serum CEA, SCC, CYFRA21-1 in patients with lung cancer and their diagnostic value with EBUS-TBNA.Journal of medical biochemistry · 2024Article
- Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024Review
- The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA.Heliyon · 2024Article
- Article
- Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Association between cigarette smoking history, metabolic phenotypes, andJournal of thoracic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe high incidence of epidermal growth factor receptor (EGFR) mutations is usually found in female patients with lung adenocarcinoma who have never-smoked. However, reports concerning male patients are scarce. Thus, this study aimed to explore a novel approach based on
methodsA total of 121 male patients with NSCLC were analyzed between October 2019 and March 2022. All patients underwent
resultsEGFR mutations were detected in 39 patients (32.2%). Compared with patients with EGFR wild-type, EGFR-mutant patients had lower concentrations of serum CYRFA21-1 (2.65 vs. 4.01, P = 0.002) and SCC-Ag (0.67 vs. 1.05, P = 0.006). No significant differences of CEA, NSE, CA 50, CA125, CA72-4 and ferritin were found between the two groups. The presence of EGFR mutations was significantly associated with low pSUV
conclusionsWe demonstrated that low concentrations of CYFRA21-1 and SCC-Ag, as well as low pSUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.